| 前收盘价格 | 10.34 |
| 收盘价格 | 10.40 |
| 成交量 | 540,506 |
| 平均成交量 (3个月) | 1,320,821 |
| 市值 | 537,669,440 |
| 价格/销量 (P/S) | 195.11 |
| 股市价格/股市净资产 (P/B) | 1.66 |
| 52周波幅 | |
| 利润日期 | 5 May 2026 |
| 营业利益率 (TTM) | -5,656.01% |
| 稀释每股收益 (EPS TTM) | -1.67 |
| 季度收入增长率 (YOY) | -11.60% |
| 总债务/股东权益 (D/E MRQ) | 0.38% |
| 流动比率 (MRQ) | 47.43 |
| 营业现金流 (OCF TTM) | -82.78 M |
| 杠杆自由现金流 (LFCF TTM) | -70.18 M |
| 资产报酬率 (ROA TTM) | -16.91% |
| 股东权益报酬率 (ROE TTM) | -28.62% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Upstream Bio, Inc. | 混合的 | 看跌 |
AIStockmoo 评分
| 分析师共识 | 2.0 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 2.0 |
| 平均 | 0.50 |
|
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases. Verekitug has advanced into three separate world-wide, placebo-controlled, randomized Phase 2 clinical trials, two completed in chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma, and one ongoing in chronic obstructive pulmonary disease (COPD). |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 14.84% |
| 机构持股比例 | 89.32% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Decheng Capital Llc | 31 Dec 2025 | 3,143,078 |
| Altshuler Shaham Ltd | 31 Dec 2025 | 1,341,540 |
| Bain Capital Life Sciences Investors, Llc | 31 Dec 2025 | 1,329,544 |
| Omega Fund Management, Llc | 31 Dec 2025 | 1,326,293 |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合